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Rett syndrome is a neurological disorder caused by loss of function of methyl-CpG-binding
protein 2 (MeCP2). Reduced function of this ubiquitous transcriptional regulator has
a devastating effect on the central nervous system. One of the most severe and
life-threatening presentations of this syndrome is brainstem dysfunction, which results
in autonomic disturbances such as breathing deficits, typified by episodes of breathing
cessation intercalated with episodes of hyperventilation or irregular breathing. Defects
in numerous neurotransmitter systems have been observed in Rett syndrome both in
animal models and patients. Here we dedicate special attention to serotonin due to its
role in promoting regular breathing, increasing vagal tone, regulating mood, alleviating
Parkinsonian-like symptoms and potential for therapeutic translation. A promising new
symptomatic strategy currently focuses on regulation of serotonergic function using highly
selective serotonin type 1A (5-HT1A) “biased agonists.” We address this newly emerging
therapy for respiratory brainstem dysfunction and challenges for translation with a holistic
perspective of Rett syndrome, considering potential mood and motor effects.
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Rett syndrome (RTT) is a neurological disorder caused by
loss of function of methyl-CpG-binding protein 2 (MeCP2).
This syndrome is most often linked to mutations in the X-
linked gene that encodes this protein. The loss of function
of this ubiquitous transcriptional regulator has a devastating
effect in particular on the central nervous system. The syn-
drome presents with cortical features, including severe mental
disability and epilepsy (Dolce et al., 2013); and extrapyrami-
dal symptoms, resulting in dystonia and dyskinesia (Chahrour
and Zoghbi, 2007). However, a life-threatening presentation of
this syndrome is the brainstem dysfunction, which results in
breathing disturbances. This phenotype, mimicked by the mouse
models of RTT, is deemed the most reliable outcome measure
for clinical translation (Katz et al., 2012). Like most pheno-
types in RTT, the presentation of respiratory disturbances is
highly variable, but typically includes episodes of breathing ces-
sation interspersed with hyperventilation or irregular breathing
(Ramirez et al., 2013). Defects in various neurotransmitter sys-
tems have been observed in patients and animal models of Rett
syndrome (Weng et al., 2011), but we believe serotonin (5-HT)
deserves particular interest due to its role in promoting regu-
lar breathing and potential for translation. A “silver bullet” is
unlikely to exist but a promising symptomatic strategy currently
focuses on regulation of serotonergic function using highly selec-
tive serotonin type 1A agonists (5-HT1A). Here we address this
newly emerging therapy for respiratory brainstem dysfunction
in Rett syndrome and challenges for translation with a holistic
perspective.
SEROTONIN AND AUTONOMIC CONTROL IN RETT
SYNDROME
Deficiencies of 5-HT neurotransmission have been found both in
humans suffering from Rett syndrome and in mouse models of
the disease. In women with known MeCP2 mutations who met
the clinical criteria for Rett syndrome, low spinal fluid levels of
a 5-HT metabolite were found (Samaco et al., 2009). Low levels
of 5-HT were also found in the brain of MeCP2 knockout male
mice and were progressive with development (Ide et al., 2005;
Viemari et al., 2005). But brain concentrations of tryptophan, the
serotonin precursor, were comparable to wild-type control mice
suggesting a failure of biosynthesis of serotonin (Ide et al., 2005).
Serotonin is an important regulatory neurotransmitter in
the respiratory network. Generally it has a modulatory effect
on breathing, increasing or decreasing post-synaptic excitabil-
ity depending on the types of receptors expressed. Overall,
the effect of 5-HT results in net stimulation of ventilation,
and it is a significant component of ventilatory responses to
CO2 (Richerson, 2004). Global deletion or acute inhibition
of serotoninergic neurons in mice results in blunted respira-
tory responses to CO2 challenges (Hodges et al., 2008; Ray
et al., 2011). Deletion of MeCP2 in male mice reduced CO2
sensitivity (Zhang et al., 2011) and selective blockade of sero-
tonin re-uptake with citalopram corrected it (Toward et al.,
2013). Recently, female mice with two different MeCP2 muta-
tions have shown depressed CO2 chemosensitivity (Bissonnette
et al., 2014). Imbalance in CO2 homeostasis was also found in
human patients (Smeets et al., 2006). Forceful breathing and
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hyperventilation are a common occurrence in between episodes
of apnea, and often result in hypocapnia (Smeets et al., 2006;
Halbach et al., 2012). This combined with an upwards-shifted
apneic threshold (Toward et al., 2013) could contribute to
episodes of central apnea and oxygen desaturation (Southall
et al., 1988). Hypocapnia and low oxygen can be powerful trig-
gers of seizures or epilepsy-like episodes in Rett syndrome. In
one patient, described as a forceful breather with epochs of
Valsalva maneuvers, such episodes were successfully managed
by administration of CO2 to correct hypocapnia (Smeets et al.,
2006).
In addition to CO2 homeostasis, serotonin is also thought
to promote regular breathing via activation of 5-HT1A recep-
tors in key brainstem sites involved in termination of inspiration
(Richter et al., 2003). A 5-HT1A partial agonist, buspirone, has
been used to treat apneusis caused by surgical resection of a
pontine astrocytoma in human (Wilken et al., 1997) and abnor-
mal breathing in Rett syndrome (Andaku et al., 2005; Gokben
et al., 2012). Systemic administration of a 5-HT1A/7 agonist,
(R)-(+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide
(+8-OH-DPAT) has also abolished spontaneous central apneas
both in wild-type mice (Stettner et al., 2008) and MeCP2 defi-
cient female mice (Abdala et al., 2010). More recently, systemic
administration of 5-HT1A agonists produced some of the most
robust rescue of respiratory phenotype yet observed in multiple
mouse models of Rett syndrome (Levitt et al., 2013; Abdala et al.,
in press).
Figure 1 summarizes multiple suggested mechanisms for gen-
eration of breathing irregularity in Rett syndrome observed in
mouse models and the potential ponto-medullary targets for 5-
HT1A agonists. It is noteworthy that 5-HT receptors are expressed
in diverse brainstem regions and can mediate additive or oppos-
ing effects on respiratory control. For instance, activation of
5-HT1A somatodendritic autoreceptors on raphe serotoninergic
neurons reduced CO2 sensitivity (Corcoran et al., 2013) a poten-
tially undesirable effect in RTT. However, a selective agonist of
5-HT1A post-synaptic heteroreceptors effectively corrected the
respiratory phenotype in a mouse model of RTT (Levitt et al.,
2013). This suggests that the beneficial effects of 5-HT1Aagonists
on breathing are chiefly mediated by heteroreceptors.
Serotonin is also important for cardiac sympatho-vagal bal-
ance. Serotoninergic agonists shift the equilibrium between car-
diac sympathetic and vagal drives toward the latter, which has
a protective effect against ventricular fibrillation (Lehnert et al.,
1987; McCall et al., 1994; Chen et al., 2008). Chen et al.
(2008) showed that a 5-HT1A/7 agonist disinhibited vagal motor
neurons via reduction of inputs from inhibitory neurons. In
mice, deletion of 5-HT1A receptors increased the susceptibil-
ity to sudden cardiac death under chronic stress (Carnevali
et al., 2012). Interestingly, girls with Rett syndrome present
reduced heart rate variability, as consequence of a reduced vagal
tonus, which correlated with lower plasma levels of serotonin
(Guideri et al., 1999, 2004). The reduced vagal tonus is pro-
gressive with development and clinical stage, and may explain
the high risk of sudden death in Rett syndrome (Kerr et al.,
1997; Guideri et al., 2001). In a cohort of patients with nor-
mal cardiac vagal drive, the increase of vagal tonus induced
FIGURE 1 | Suggested mechanisms for respiratory rhythm disease in
Rett syndrome and network targets of 5-HT1A agonists. Populations of
respiratory neurons are shown in white circles (see below). Blue arrows
indicate excitatory drive; red connectors with circle-ends indicate inhibitory
drive. A healthy respiratory rhythm and pattern are critically dependent on
the balance between excitatory and inhibitory synaptic drives to the “core”
of mutually inhibitory respiratory neurons located in the BötC and pre-BötC
(Smith et al., 2013). The disturbed rhythm in Rett syndrome seems to arise
from an imbalance of drives to this core circuitry (indicated by black “X”
when reduced, or blue “+” when enhanced); many mechanisms contribute
to this: (i) weakened excitatory synaptic drives to and within the inspiratory
“kernel” (Viemari et al., 2005), (ii) reduced CO2 sensitivity (Zhang et al.,
2011; Toward et al., 2013; Bissonnette et al., 2014); (iii) excess descending
post-inspiratory drive from the pontine parabrachial complex (Stettner et al.,
2007; Voituron et al., 2010; Dhingra et al., 2013); which could be a
consequence of loss of inhibitory drives to this area, including KF (Stettner
et al., 2007; Abdala et al., 2010). In combination, these mechanisms would
lead to disinhibition of PI populations, disruption of timing for termination of
inspiration and expiratory length irregularity. Studies in humans and mice
suggest that breath-holds and Valsalva maneuvers may be linked to active
closure of the glottis implicating a failure in the ponto-medullary gating of
central post-inspiratory activity, for a review; see Ramirez et al. (2013).
5-HT1A receptors suppress specific inhibitory glycinergic neuron
populations in the “core” of mutually inhibitory neurons with consequent
disinhibition of inspiratory populations (Shevtsova et al., 2011). In addition,
5-HT1A receptors can directly reduce the activity of neuron populations
contributing to the descending post-inspiratory drive from the pons. I,
inspiratory neuron population; PI, post-inspiratory neuron population; E2,
late expiratory neuron population; PR, pulmonary stretch relay; LBP, lateral
parabrachial nu; KF, Kölliker-Fuse nu; NTS, nucleus of the solitary tract; RTN,
retrotrapezoid nu; BötC, Bötzinger complex; pre-BötC, pre-Bötzinger
complex.
by selective 5-HT1A agonists would be an undesirable side
effect, placing them at risk of atrial arrhythmias. In patients
with Rett syndrome, who display a shifted set point of car-
diac parasympathetic drive, the increase of vagal tonus induced
by selective 5-HT1A agonists would be a particularly desirable
effect.
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SLEEP DISORDERED BREATHING IN RETT SYNDROME
Another likely contributor for sympathetic overactivity in Rett
syndrome is sleep disordered breathing. Recent polysomnography
recordings in girls with Rett syndrome revealed that obstruc-
tive sleep apneas (OSAs) are highly prevalent in this popula-
tion. During sleep, central apneas are less frequent and shorter
when compared to wakefulness (Weese-Mayer et al., 2008). Even
though central apneas are 10–30%more frequent than OSAs dur-
ing sleep, the latter are clinically relevant in approximately 50% of
the patients investigated, causing life threatening oxygen desatu-
rations (SpO2 < 75%) (Hagebeuk et al., 2012; Carotenuto et al.,
2013). In children, severe OSA has clear health implications, the
common symptoms are: frequent awakenings, night terrors, poor
concentration, irritability, behavioral problems, failure to thrive,
enuresis, attention-deficit disorder, cardiopulmonary disease, and
excessive daytime sleepiness (Waters et al., 2013). Most of these
symptoms are easily confounded with the symptomatology of
Rett syndrome itself. Unfortunately, this means that often, from
a clinician’s point of view, OSA diagnosis and treatment is not a
priority in Rett patients.
In fact, the high prevalence of OSAs is relevant for the
treatment of respiratory disturbances in Rett syndrome since
they have potential to generate a reciprocal feedback loop with
central apneas resulting in respiratory irregularities. It is well
established that OSAs increase peripheral chemoreceptor sensi-
tivity in humans independently of other underlying conditions
(Narkiewicz et al., 1999). In turn, excess activation of the periph-
eral chemoreceptor reflex during apnea-induced desaturations
in Rett syndrome, could aggravate hyperventilation episodes
in between apneas and generate hypocapnia. This type of res-
piratory overshoot is particularly undesirable during sleep, as
PaCO2 reaches the apneic threshold resulting in periodic breath-
ing (Dempsey et al., 2014). An overactive chemoreflex could also
account for the sympatho-vagal imbalance common in patients
with Rett (Guideri et al., 1999).
A pharmacotherapy capable of addressing all legs of this feed-
back loop would stand better chances of success in clinical prac-
tice. It is thought that, in the supine position, recruitment of the
genioglossus can open a collapsed airway before arousal (Younes
et al., 2012). For that reason, mechanisms that facilitate recruit-
ment of hypoglossal motor neurons are an attractive target for
pharmacotherapy. Rodent models revealed that the respiratory
component of genioglossal activity is increased by 5-HT1A recep-
tor activation, a potentially beneficial effect (Besnard et al., 2007).
Another potentially advantageous effect of this class of drugs is
the reduction of epochs of REM sleep (Monti and Monti, 2000),
since OSAs mostly occur in this phase. The lack of success in
previous clinical trials (Kohler et al., 2009) using various older
serotonin agonists may be due to their lack of receptor selectiv-
ity, weak partial agonism and/or poor pharmacokinetics (Fiorino
et al., in press).
SEROTONIN AND MOOD CONTROL IN RETT SYNDROME
Particularly in Rett syndrome, mood disorder should not be
viewed as a separate entity to autonomic dysfunction, as anxiety
features could have a role in episodes of hyperventilation. Southall
et al. (1988) observed that hyperventilation only occurred in
wakefulness and was not necessarily preceded by hypoxemia,
which suggests a central origin. Prolonged absences of inspi-
ratory effort always followed hyperventilation. These girls also
seemed agitated with increased muscle tonus and elevated
heart rate, suggesting that anxiety may underlie these symp-
toms. SSRIs such as citalopram or fluoxetine are commonly
used to treat anxiety disorders in a clinical setting. By pre-
venting reuptake of 5-HT, these drugs modify serotonin lev-
els and, indirectly, activation of serotonin receptors. It should
also be noted that 5-HT receptors are expressed in diverse
brain regions and can mediate complementary or sometimes
opposing influence on mood and cognition (Newman-Tancredi,
2011). For example, activation of 5-HT1A autoreceptors in
the raphe nuclei can totally suppress electrical activity of
serotonergic neurons and thus powerfully inhibit serotonin
release in neuronal projection areas (Celada et al., 2013). In
contrast, activation of post-synaptic cortical 5-HT1A hetero-
receptors expressed on glutamatergic pyramidal cells and/or
GABAergic interneurons, elicits increased dopamine release in
cortex (Santana et al., 2004; Bortolozzi et al., 2010), an effect
which is associated with beneficial effects on mood deficits as
well as positive effects on cognitive function (Phillips et al.,
2004).
In the case of RTT patients, lower basal levels of 5-HT are
reported (see above) and some of the mood deficits observed
in Rett syndrome patients may therefore arise from deficien-
cies in serotonergic transmission (particularly via 5-HT1A recep-
tors) in specific brain regions. Such a hypothesis is reinforced
by transgenic mouse studies that have provided insight into
the developmental role of 5-HT1A receptors (Akimova et al.,
2009; Garcia-Garcia et al., 2014). Thus, mice with a genetically-
elicited deletion of 5-HT1A receptors (5-HT1A KO mice) exhibit
heightened anxiety-like behavior, as do mice with a heterozy-
gote 5-HT1A genotype that express about half of normal lev-
els of 5-HT1A receptor density. This suggests that even partial
decreases in 5-HT1A receptor expression (which may mimic
the impaired serotonergic transmission observed in Rett syn-
drome) can elicit phenotypically-meaningful increases in anxiety
levels. In contrast, when mice were engineered to overexpress
5-HT1A receptors (Kusserow et al., 2004), they exhibited the
opposite phenotype, with decreased anxiety-like behavior and
increased hippocampal and striatal levels of serotonin. An addi-
tional study investigated the reversal of the anxiety-like phe-
notype of 5-HT1A KO mice. In these mice, 5-HT1A receptors
were overexpressed in pyramidal neurons (but not GABAergic
interneurons; Gross et al., 2002), in various forebrain regions,
and this re-established normal behavioral responses. This study
is significant because it shows that the “anxious” phenotype of
the KO mice can be rescued, if 5-HT1A receptor signaling is rein-
troduced to the relevant brain regions. Such observations support
the assertion that treatments that augment 5-HT1A receptor sig-
naling in appropriate forebrain structures can attenuate anxiety
symptoms.
The possibility that mood deficits seen in Rett syndrome
patients arise from neurodevelopmental disruption of 5-HT1A
receptor expression is reinforced by studies showing that undis-
turbed expression of the 5-HT1Areceptor is required in the 2nd
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and 3rd week of life for the emergence of a normal anxiety-like
phenotype. Indeed, genetic disruption of 5-HT1A receptors in
mice at this time period elicits development of pathological lev-
els of anxiety (Gross et al., 2002; Leonardo and Hen, 2008), an
observation that can be mimicked by pharmacological blockade
of 5-HT1A receptors (Lo Iacono and Gross, 2008).
Taken together, the above considerations suggest that acti-
vation of 5-HT1A receptors by administration of agonist drugs
to Rett patients could attenuate anxiety symptoms in adults. In
addition, if the heightened anxiety symptoms are the result of
insufficient serotonergic activation during development, it may
be speculated that treatment with a 5-HT1A agonist at a young
age may exert some measure of protection against the emergence
of later anxiety symptoms. Nevertheless, considerable additional
investigation is necessary to substantiate such hypotheses, notably
because none of the above studies on transgenic 5-HT1A mice was
carried out in female MeCP2+/− mice modeling Rett syndrome.
Indeed, studies of anxiety-like behavior in MeCP2+/− mice
have yielded somewhat divergent data. One study found that
MeCP2+/− female mice exhibited lower anxiety-like behavior in
two different tests (Samaco et al., 2013). In contrast, another
study in male mice expressing a truncated allele of MeCP2
(MeCP2108/y) (McGill et al., 2006) found that MeCP2+/− mice
show responses that are typical of increased anxiety in the
same tests. The relationship between these observations and the
heightened anxiety observed in individuals with Rett syndrome
is unclear, but there is a clear need for additional investigation
of anxiety-like behavior in RTT mice, particularly in response
to clinically-employed anxiolytic drugs and 5-HT1A receptor
agonists.
DOPAMINERGIC INTERACTIONS OF SEROTONINERGIC
AGONISTS: IMPLICATIONS FOR MOTOR FUNCTION IN RETT
SYNDROME
In women with known MeCP2 mutations who met the clinical
criteria for Rett syndrome, low spinal fluid levels of a dopamine
metabolite were found (Samaco et al., 2009). Assuming that this
is a marker for central dopamine levels, it may provide a neu-
rochemical substrate for the devastating disturbances in motor
function observed in Rett syndrome, characterized by loss of pur-
poseful use of the hands, ataxia, tremors, gait apraxia, rigidity,
and dystonia. Another indicator of compromised dopaminergic
Table 1 | Drugs currently under clinical testing that possess serotonin 5-HT1A receptor agonist activity.
Drug Clinical indication Trade name® or Company Mechanism of action References
highest development
Buspirone Anxiety (GAD) Buspar® BMS 5-HT1A partial agonist, D2
antagonist
Akimova et al., 2009
Tandospirone Anxiety (GAD) Sediel® Dainippon
Sumitomo
5-HT1A partial agonist, D2
antagonist
Meltzer and
Sumiyoshi, 2008
Vilazodone Depression Viibryd® Clinical
Data
SRI, 5-HT1A partial agonist Dawson and
Watson, 2009
Vortioxetine Depression Brintellix® Lundbeck/
Takeda
SRI; 5-HT1A and 5-HT1Bpartial
agonist; 5-HT1D, 5-HT3 and
5-HT7antagonist
Mork et al., 2009
Flibanserin Female hypoactive
sexual desire disorder
Phase III Sprout 5-HT1A agonist, 5-HT2A
antagonist, D4 partial agonist
Stahl et al., 2011
Sarizotan L- DOPA-induced
dyskinesia in
Parkinson’s diseasea
Phase III Newron 5-HT1A agonist, D2 partial
agonist
Bartoszyk et al.,
2004
Befiradol L- DOPA-induced
dyskinesia in
Parkinson’s disease
Phase II Neurolixis Selective 5-HT1A full agonist Colpaert, 2006
Eltoprazine L- DOPA-induced
dyskinesia in
Parkinson’s disease
Phase II Amarantus 5-HT1A and 5-HT1Bpartial
agonist, 5-HT2A, 5-HT2B,
5-HT2C
Bezard et al., 2013
NLX-101
(F15599)
Rett syndrome Phase I Neurolixis Selective post-synaptic 5-HT1A
“biased agonist”
Levitt et al., 2013
GAD, Generalized Anxiety Disorder; SRI, Serotonin Reuptake Inhibitor.
aSarizotan may also be developed for Rett syndrome (http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=141).
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transmission is that, later in life, the women with Rett develop
Parkinsonian features (Fitzgerald et al., 1990; Roze et al., 2007).
The precise role of serotonin in Rett syndrome motor deficits
in currently unclear but some analogies may be drawn from
the use of serotonergic agonists in the treatment of Parkinson’s
disease (PD)—which is also characterized by dopaminergic
deficiencies leading to motor impairment. For example (i) 5-
HT1A receptor agonists reverse catalepsy induced by blockade
of dopamine receptors with neuroleptics (McMillen et al., 1988;
Wadenberg, 1996); (ii) (+)-8-OH-DPAT and sarizotan reduced
L-DOPA-induced dyskinesia in monkeys with lesioned dopamin-
ergic neurons in the substantia nigra (Iravani et al., 2006; Gregoire
et al., 2009; Marin et al., 2009); and (iii) in clinical trials, sari-
zotan, buspirone, and tandospirone alleviated dyskinesia in PD
patients (Bonifati et al., 1994; Kannari et al., 2002). At a neu-
rochemical level, 5-HT1A receptor agonists increase dopamine
release in frontal cortex, as mentioned above, and modify the
activity of cortico-striatal glutamatergic projections. Such influ-
ence, possibly involving inhibition of glutamate in the striatum
may underlie the capacity of 5-HT1A receptor agonists to facilitate
movement control (Dupre et al., 2011; Huot et al., 2011). Table 1
lists drugs currently under clinical testing that possess serotonin
5-HT1A receptor agonist activity.
Insofar as such observations may be relevant to Rett syn-
drome, they suggest that activation of 5-HT1A receptors may
alleviate some of the disturbed motor function, including dysk-
inesia and dystonia, which constitute a source of poor movement
control in RTT patients. Nevertheless, experimental investiga-
tion is necessary to substantiate this hypothesis, for example by
examining the motor sensitivity of MeCP2 mice to dopamine
receptor blockade (catalepsy induction) and whether 5-HT1A
receptor agonists can protect against such responses. It should
also be noted that the therapeutic potential of current 5-HT1A
agonists suffers from some important limitations. Prominent
among these is poor selectivity of the drugs with respect to cross-
reacting targets. Indeed, buspirone also acts as a dopamine D2
receptor antagonist (Peroutka, 1985), and sarizotan is a weak
D2 receptor partial agonist (Bartoszyk et al., 2004; Newman-
Tancredi et al., 2005; Bruins Slot et al., 2006), and may act as
a functional antagonist. This suggests again that high selectiv-
ity for 5-HT1A receptors is an important requirement to avoid
concurrent off-target blockade of dopamine receptors. Secondly,
drugs such as eltoprazine, buspirone, and tandospirone possess
only modest agonist efficacy at 5-HT1A receptors. Thus, even
at high doses, they are only able to partially activate the recep-
tor (Newman-Tancredi et al., 2003), suggesting that optimal
motor control by 5-HT1A receptors may necessitate high-efficacy
agonist stimulation. The novel 5-HT1A receptor agonist, NLX-
101 (also known as F15599) constitutes a promising advance
in view of its exceptional 5-HT1A receptor selectivity, high ago-
nist efficacy and “biased agonist” profile (Newman-Tancredi
et al., 2009), potently activating post-synaptic cortical 5-HT1A
heteroreceptors (Llado-Pelfort et al., 2010). In vivo, NLX-101
exhibits pro-motor influence in rats with dopaminergic lesions,
potent antidepressant-like properties (Assie et al., 2010), pro-
cognitive activity (Depoortere et al., 2010); and, in MeCP2 mice,
reverses respiratory disturbance (Levitt et al., 2013), properties
that would be desirable in a pharmacotherapy strategy for Rett
syndrome.
CONCLUSIONS
The severe autonomic phenotype of Rett syndrome has the great-
est impact on patient’s health and quality of life, closely followed
by motor deficits. 5-HT1A agonists have shown promising ability
to alleviate brainstem, extrapyramidal and mood dysfunction in
pre-clinical studies. In particular, a new class of selective “biased
agonists” that target post-synaptic heteroreceptors shows less
potential for competing or undesirable side effects. However, fur-
ther rigorous pre-clinical testing in different mouse models of
Rett syndrome is needed, especially in regards to motor dys-
function. In mouse models, the syndrome is reversible if MeCP2
function is rescued, but a cure applicable to humans is uncertain
and may be many years away. In the meantime, there is need for
drug therapies that are tolerated upon long term treatment and
capable of alleviating the life-threatening autonomic symptoms.
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